In RA, TNFi-treatment decreased the frequency of circulating classical monocytes and the number of osteoclasts developed from total peripheral blood mononuclear cell (PBMC) stimulation with RANKL and M-CSF [35]. The gene discussed is TNFSF11; the disease is rheumatoid arthritis.